BE905736A - Compositions pharmaceutiques comprenant du chrome destinees a etre utilisees dans le traitement de l'arteriosclerose. - Google Patents
Compositions pharmaceutiques comprenant du chrome destinees a etre utilisees dans le traitement de l'arteriosclerose. Download PDFInfo
- Publication number
- BE905736A BE905736A BE0/217396A BE217396A BE905736A BE 905736 A BE905736 A BE 905736A BE 0/217396 A BE0/217396 A BE 0/217396A BE 217396 A BE217396 A BE 217396A BE 905736 A BE905736 A BE 905736A
- Authority
- BE
- Belgium
- Prior art keywords
- iii
- medicament
- pharmaceutical composition
- trivalent chromium
- treatment
- Prior art date
Links
- 239000011651 chromium Substances 0.000 title claims abstract description 107
- 206010003210 Arteriosclerosis Diseases 0.000 title claims abstract description 23
- 208000011775 arteriosclerosis disease Diseases 0.000 title claims abstract description 23
- 229910052804 chromium Inorganic materials 0.000 title claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 19
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 title description 20
- 239000003814 drug Substances 0.000 claims abstract description 40
- 150000001845 chromium compounds Chemical class 0.000 claims abstract description 17
- 241000124008 Mammalia Species 0.000 claims abstract description 13
- 230000006872 improvement Effects 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000005985 organic acids Nutrition 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- 150000007522 mineralic acids Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 241000282412 Homo Species 0.000 description 5
- QLOKJRIVRGCVIM-UHFFFAOYSA-N 1-[(4-methylsulfanylphenyl)methyl]piperazine Chemical compound C1=CC(SC)=CC=C1CN1CCNCC1 QLOKJRIVRGCVIM-UHFFFAOYSA-N 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 238000009142 chromium supplementation Methods 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- JOPOVCBBYLSVDA-UHFFFAOYSA-N chromium(6+) Chemical compound [Cr+6] JOPOVCBBYLSVDA-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL77075A IL77075A (en) | 1985-11-17 | 1985-11-17 | Pharmaceutical compositions comprising chromium for use in the treatment of atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE905736A true BE905736A (fr) | 1987-03-02 |
Family
ID=11056431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE0/217396A BE905736A (fr) | 1985-11-17 | 1986-11-12 | Compositions pharmaceutiques comprenant du chrome destinees a etre utilisees dans le traitement de l'arteriosclerose. |
Country Status (2)
| Country | Link |
|---|---|
| BE (1) | BE905736A (enrdf_load_stackoverflow) |
| IL (1) | IL77075A (enrdf_load_stackoverflow) |
-
1985
- 1985-11-17 IL IL77075A patent/IL77075A/xx unknown
-
1986
- 1986-11-12 BE BE0/217396A patent/BE905736A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL77075A0 (enrdf_load_stackoverflow) | 1986-04-29 |
| IL77075A (en) | 1989-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7442095B2 (ja) | ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法 | |
| EP0986376B1 (fr) | Utilisation d'un oligosaccharide INHIBITEUR DU FACTEUR Xa EN COMBINAISON AVEC UN ANTIAGREGANT PLAQUETTAIRE pour le traitement de LA THROMBOSE ARTERIELLE | |
| FR2774591A1 (fr) | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie | |
| JP6092843B2 (ja) | 神経障害の治療用組成物 | |
| JP2000517339A (ja) | 脂肪酸による治療 | |
| CA2268876A1 (fr) | Le (-)hydroxycitrate de magnesium, procede de preparation, applications, et compositions notamment pharmaceutiques le renfermant | |
| KR101734152B1 (ko) | 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체 | |
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| FR2490493A1 (fr) | Composition pharmaceutique ou alimentaire contenant de l'a -cetoglutarate de pyridoxine, procede pour sa preparation | |
| JP2004534094A (ja) | 二日酔いに有効な組成物及びそのための使用 | |
| FR2530468A1 (fr) | Composition analgesique et anti-inflammatoire contenant de l'ibuprofen | |
| FR2497510A1 (fr) | Composition pharmaceutique contenant de la g-butyrobetaine pour le traitement des syndromes provoques par une carence en l-carnitine | |
| JPH09509139A (ja) | 酪酸エステル細胞分化薬 | |
| HUE029493T2 (en) | Composition for the treatment of infertility | |
| EP1526850B1 (fr) | Utilisation de la vitamine C pour le traitement de la maladie de Charcot-Marie-Tooth | |
| US4291030A (en) | Method of lowering blood cholesterol | |
| JPH0699310B2 (ja) | アセトアルデヒド解毒剤 | |
| EP1450782B1 (en) | Use of a combination composition comprising propionyl l-carnitine and further drugs for the treatment of erectile dysfunction | |
| BE905736A (fr) | Compositions pharmaceutiques comprenant du chrome destinees a etre utilisees dans le traitement de l'arteriosclerose. | |
| EP0739629B1 (fr) | Nouvelles associations comprenant du (-)hydroxycitrate et présentant notamment de nouvelles activités thérapeutiques | |
| BE897378A (fr) | Procede pour prevenir la fievre de lait chez la vache laitiere | |
| JPH01186883A (ja) | 抗アテローム性動脈硬化症剤としてのｄｌ‐５‐〔（２ベンジル‐３，４‐ジヒドロ‐２Ｈ‐ベンゾピラン‐６‐イル）メチル〕チアゾリジン‐２，４‐ジオン | |
| WO1991007960A1 (fr) | Compositions pharmaceutiques destinees au traitement de l'ataxie et les troubles de l'equilibre | |
| FR2530624A1 (fr) | Nouveaux analogues de la vitamine d et compositions pharmaceutiques ou veterinaires les contenant | |
| FR2515961A1 (fr) | Preparations medicamenteuses contenant un derive d'acide tetraiodothyrocarboxylique notamment pour le traitement de l'hypercholesterolemie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: SHAARE ZEDEK MEDICAL CENTER Effective date: 19891130 |